

Alpha Synuclein - Pipeline Review, H2 2019

<https://marketpublishers.com/r/A214B45D7E9AEN.html>

Date: August 2019

Pages: 126

Price: US\$ 3,500.00 (Single User License)

ID: A214B45D7E9AEN

Abstracts

Alpha Synuclein - Pipeline Review, H2 2019

SUMMARY

Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Alpha-synuclein is a protein normally found in cells all over the body. It is one of the key players in Parkinson's. In Parkinson's it forms clumps inside the specific nerve cells that produce the chemical dopamine. It is involved in the regulation of dopamine release and transport. It induces fibrillization of microtubule-associated protein tau. It reduces neuronal responsiveness to various apoptotic stimuli, leading to decreased caspase-3 activation.

Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) pipeline Target constitutes close to 51 molecules. Out of which approximately 42 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 4, 9, 19 and 10 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 8 and 1 molecules, respectively.

Report covers products from therapy areas Central Nervous System, Metabolic Disorders, Cardiovascular, Gastrointestinal, Genetic Disorders, Infectious Disease and Ophthalmology which include indications Parkinson's Disease, Alzheimer's Disease, Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration), Neurodegenerative Diseases, Lewy Body Dementia, Familial Amyloid Neuropathies, Amyloidosis, Constipation, Dementia, Dementia Associated With Alzheimer's Disease, Down Syndrome, Glaucoma, Human Immunodeficiency Virus (HIV) Infections (AIDS), Schizophrenia, Spinal Cord Injury, Stroke, Traumatic Brain

Injury and Type 2 Diabetes.

The latest report Alpha Synuclein - Pipeline Review, H2 2019, outlays comprehensive information on the Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA)

The report reviews Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Alpha Synuclein (Non A Beta

Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics and enlists all their major and minor projects

The report assesses Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Alpha

Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Overview

Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Companies Involved in Therapeutics

Development

AbbVie Inc

AC Immune SA

AFFiRiS AG

Annovis Bio Inc

Arvinas Inc

AstraZeneca Plc

Biogen Inc

Denali Therapeutics Inc

Enterin Inc

Fulcrum Therapeutics Inc

Genmab A/S

ICB International Inc

Neuropore Therapies Inc

nLife Therapeutics SL

Prevail Therapeutics Inc

Priavoid GmbH

ProMIS Neurosciences Inc

Prothena Corp Plc

Seelos Therapeutics Inc

UCB SA

United Neuroscience Ltd

Voyager Therapeutics Inc

Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Drug Profiles

ABBV-0805 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ABL-301 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antibodies to Inhibit Alpha-Synuclein for Glaucoma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antibody to Inhibit Alpha Synuclein for Parkinson's Disease and Multiple System Atrophy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antibody to Inhibit Alpha-Synuclein for Neurodegenerative Diseases and Parkinson's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antisense Oligonucleotides to Inhibit LRRK2 and SNCA for Parkinson's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ANVS-401 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ANVS-405 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASOA-19 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AV-1947D - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AV-1948D - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AV-1949D - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AV-1950D - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AV-1950R - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bispecific Monoclonal Antibodies to Inhibit SNCA for Parkinson's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cinpanemab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CLR-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DPC-003 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug to Inhibit Alpha Synuclein for Parkinson's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ENT-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fusion Proteins to Inhibit ABPP, MAPT and NACP for Amyloidosis and Neurodegenerative Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapies to Inhibit SNCA for Neurology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Inhibit Alpha Synuclein for Parkinson's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LuAF-82422 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MEDI-1341 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit Alpha Synuclein for Parkinson's Disease and Lewy Body Dementia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit Tau, Amyloid Beta and Alpha-Synuclein for Neurodegenerative Diseases - Drug Profile

Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit Alpha Synuclein for Central Nervous System Disorders -
Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NLFPD-1233 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NPT-088 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NPT-10018A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NPT-189 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NPT-20011 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PD-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PD-1601 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PD-1602 - Drug Profile
Product Description
Mechanism Of Action

R&D Progress

PP-003 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PR-004 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

prasinezumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SLS-004 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SLS-007 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Alpha Synuclein for Multiple System Atrophy and Parkinson's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Alpha-Synuclein for Neurodegenerative Diseases Parkinson's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Alpha-Synuclein for Parkinson's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit SNCA for Parkinson's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Alpha-Synuclein and Lcn2 for Parkinson's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Alpha-Synuclein for Parkinson's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Inhibit Alpha Synuclein for Parkinson's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

trehalose - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

UB-312 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

UCB-0599 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Dormant Products

Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) - Product Development Milestones

Featured News & Press Releases

Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Indication, H2 2019

Number of Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Products under Development by Companies, H2 2019 (Contd..3), H2 2019

Number of Products under Investigation by Universities/Institutes, H2 2019

Products under Investigation by Universities/Institutes, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Pipeline by AbbVie Inc, H2 2019

Pipeline by AC Immune SA, H2 2019

Pipeline by AFFiRiS AG, H2 2019

Pipeline by Annovis Bio Inc, H2 2019

Pipeline by Arvinas Inc, H2 2019

Pipeline by AstraZeneca Plc, H2 2019

Pipeline by Biogen Inc, H2 2019

Pipeline by Denali Therapeutics Inc, H2 2019

Pipeline by Enterin Inc, H2 2019

Pipeline by Fulcrum Therapeutics Inc, H2 2019

Pipeline by Genmab A/S, H2 2019

Pipeline by ICB International Inc, H2 2019

Pipeline by Neuropore Therapies Inc, H2 2019

Pipeline by nLife Therapeutics SL, H2 2019

Pipeline by Prevail Therapeutics Inc, H2 2019

Pipeline by Priavoid GmbH, H2 2019

Pipeline by ProMIS Neurosciences Inc, H2 2019

Pipeline by Prothena Corp Plc, H2 2019

Pipeline by Seelos Therapeutics Inc, H2 2019

Pipeline by UCB SA, H2 2019

Pipeline by United Neuroscience Ltd, H2 2019

Pipeline by Voyager Therapeutics Inc, H2 2019

Dormant Products, H2 2019

Dormant Products, H2 2019 (Contd..1), H2 2019

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019

COMPANIES MENTIONED

AbbVie Inc

AC Immune SA

AFFiRiS AG

Annovis Bio Inc

Arvinas Inc

AstraZeneca Plc

Biogen Inc

Denali Therapeutics Inc

Enterin Inc

Fulcrum Therapeutics Inc

Genmab A/S

ICB International Inc

Neuropore Therapies Inc

nLife Therapeutics SL

Prevail Therapeutics Inc

Priavoid GmbH

ProMIS Neurosciences Inc

Prothena Corp Plc

Seelos Therapeutics Inc

UCB SA

United Neuroscience Ltd

Voyager Therapeutics Inc

I would like to order

Product name: Alpha Synuclein - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/A214B45D7E9AEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A214B45D7E9AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970